Oslo, 30 April 2021 - Navamedic ASA (OSE: NAVA) publishes its annual report for
2020. The report is attached and available on navamedic.com/investors.

Highlights for 2020:

  · Navamedic has made strategically important investments in its organization
and platform, including strengthening its presence and positioning in the Dutch
market and the launch of the company's patient support program. These
investments will be key as Navamedic embark 2021 and continue to launch new
products and continue to grow its existing portfolio.
  · In full-year 2020, Navamedic's revenues increased by 11.2% to NOK 209.9 (NOK
188.8 million) with an EBITDA of negative NOK 1.3 million (negative NOK 6.5
million) driven by both new product launches and investments in further growth
initiatives.
  · Gross margin improved to 33.5% (30.5%), partly due to favourable revenues
mix, reduced CoGS and other changes.
  · Strengthened the company's portfolio and offering across product categories.
In 2020, Navamedic strengthened its hospital and prescription drug offering
through the acquisition of Nordic marketing authorizations for a large hospital
antibiotics portfolio.
  · The company expanded its consumer health offering by entering a long-term
exclusive distribution agreement for ThermaCare® in the Nordics and the
Netherlands. Alflorex® launched in Denmark, Iceland and the Netherlands during
the year, and continued growth in Norway.
  · Continued strong performance for Mysimba®, accelerated by improved
reimbursement in Norway and Navamedic's patient support program.
  · Navamedic completed a private placement including a subsequent offering to
raise a total of NOK 52.4 in order to fund growth initiatives as well as general
corporate purposes.

"In 2020, we have continued the implementation of our growth strategy. We have
built on our solid foundation and strengthened our existing business by
leveraging and investing in our highly scalable market access platform. We have
focused strongly on launches of new products and will launch new products in at
least one country in each launch window going forward. We have increased value
through acquisitions of products and brands. In short, we have continued our
journey of building a leading Nordic pharma company, targeting growth in
Northern Europe," says Kathrine Gamborg Andreassen, Chief Executive Officer of
Navamedic ASA.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.